Stocks and Investing Stocks and Investing
Fri, August 4, 2023

Andrew Fein Reiterated (BCRX) at Strong Buy and Held Target at $30 on, Aug 4th, 2023


Published on 2024-10-28 05:33:45 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "BioCryst Pharmaceuticals, Inc." (BCRX) at Strong Buy and Held Target at $30 on, Aug 4th, 2023.

Andrew has made no other calls on BCRX in the last 4 months.



There are 3 other peers that have a rating on BCRX. Out of the 3 peers that are also analyzing BCRX, 0 agree with Andrew's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Andrew


  • Serge Belanger of "Needham" Reiterated at Strong Buy with Decreased Target to $12 on, Thursday, August 3rd, 2023
  • Tazeen Ahmad of "B of A Securities" Upgraded from Hold to Strong Buy and Held Target at $10 on, Thursday, July 13th, 2023
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Decreased Target to $10 on, Thursday, April 20th, 2023
Contributing Sources